Study of Chemotherapy and Patient Health Outcomes for Nausea and Emesis

Merck Sharp & Dohme LLC0 sites1,500 target enrollmentAugust 2004

ConditionsChemotherapy Induced Nausea and Vomiting

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Chemotherapy Induced Nausea and Vomiting
Sponsor: Merck Sharp & Dohme LLC
Enrollment: 1500
Primary Endpoint: CINV at the delayed phase during cycle 2
Status: Completed
Last Updated: 11 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

The purpose of this study is to assess whether timely feedback to providers on patient experiences with delayed chemotherapy induced nausea and vomiting (CINV) lead to differences in patient outcomes for subsequent cycles.

Registry

clinicaltrials.gov

Start Date

August 2004

End Date

December 2005

Last Updated

11 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Merck Sharp & Dohme LLC

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Highly or moderately emetogenic chemotherapy planned for at least 2 cycles

Exclusion Criteria

•Concurrent other anti-cancer therapy (e.g. radiation, hormone, etc.); vomiting during the 24 hours prior to first chemotherapy cycle; having a disease/condition or taking medication that may cause emesis